Leukemia treatment showdown: which works best?
NCT ID NCT02938858
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This registry study follows 400 patients with a specific type of leukemia (non-high-risk APL) who are 70 or younger. It compares two standard treatments: ATRA plus chemotherapy versus ATRA plus arsenic trioxide. The goal is to see which approach leads to better long-term outcomes and fewer side effects, helping doctors make informed treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATRA plus chemotherapy or ATRA plus arsenic trioxide (ATO)
What this could lead to
If successful, this registry could help doctors choose the best first-line treatment for non-high-risk APL, improving survival and reducing side effects.
What could go wrong
This is an observational registry, not a controlled trial, so results may be influenced by treatment choices. It does not test a new drug, so no direct breakthrough is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Dr Schaffner
Lens, 62307, France
-
CHR Metz-Thionville - Hôpital de Marcy
Metz, 57085, France
-
CHRU de Brest - Pédiatrie Spécialisée
Brest, 29609, France
-
CHU Bordeaux Pellegrin enfant
Bordeaux, 33076, France
-
CHU Estaing
Clermont-Ferrand, 63100, France
-
CHU Hôpital Sud - service Hémato-oncologie Pédiatrique
Rennes, 35203, France
-
CHU Hôtel Dieu
Nantes, 44035, France
-
CHU Saint Eloi
Montpellier, 34095, France
-
CHU de Grenoble
Grenoble, 38043, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier V. Dupouy
Argenteuil, 95107, France
-
Centre Hospitalier d'Aix en Provence
Aix-en-Provence, 13616, France
-
Chru - Hopital Claude Huriez
Lille, 59037, France
-
Chu Timone
Marseille, 13385, France
-
Groupe Hospitalier SUD
Amiens, 80054, France
-
Hopital Andre Mignot
Le Chesnay, 78150, France
-
Hôpital Henri Mondor
Créteil, 94100, France
-
Hôpital Jean Minjoz
Besançon, 25030, France
-
Hôpital Necker
Paris, 75015, France
-
Hôpital Robert Debré
Paris, 75019, France
-
Hôpital TROUSSEAU
Paris, 75012, France
-
Hôpital V. Provo
Roubaix, 59056, France
-
Hôpital de la Source
Orléans, 45100, France
-
Hôpital universitaire Dupuytren
Limoges, 87042, France
-
IUCT Oncopole
Toulouse, 31059, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut de Cancerologie de La Loire
Saint-Priest-en-Jarez, 42270, France